Three general pharmaceutical industry proposed to increase 300 million strands of electric wire and cable enterprises

NetEase Finance September 26 News of the three general pharmaceutical industry Sunday Evening issued a notice that the company intends to the controlling shareholder Far East Holdings directed issue more than 300 million shares, the acquisition of its own wire and cable business quality assets, wire and cable will become the company's new main business. No cash transaction notice shows that the price of this issue is 7.19 yuan/share, the number of shares to be issued is 30,743.26.84 million shares, the controlling shareholder Far East Holdings will be owned by its wire and cable business quality assets, including the Far East cable 100% Equity, the new Far East 100% Equity and composite Technology 100%　　Equity subscription for this targeted issue of shares, this transaction does not involve cash transactions. The value of the target asset appreciation rate is 147.1% according to the Asset assessment report, the benchmark assets account value of 89,454.100,000 yuan and the valuation rate is 147.1% by September 30, 2008 as the base date for the assessment.　　This transaction asset price is 221,044.100,000 yuan.　　Far East Holdings will be the absolute holding of this issue, the Far East holding three general pharmaceutical 27.96% of the shares, the completion of this issue, the Far East holding shareholding will rise to 79.77%, in an absolute holding position.　　The three-Pu pharmaceutical industry said that the transaction constitutes a cross-linked transaction, and trigger an offer to purchase obligations, Far East holdings to apply for exemption from the takeover obligation. Wire and cable will become the main business before this transaction, the three main pharmaceutical industry for the production and sale of pharmaceutical products. After the completion of the transaction, wire and cable will become the company's new business, and in the main business of the proportion will be significantly more than the pharmaceutical business, the three general pharmaceutical industry, said the company is facing changes in the main business risk.　　When the relevant assets, business and personnel enter the company with the reorganization, if the company can not carry out effective management, it will affect the market competitiveness of injected assets, thus affecting the company's economic benefits. Be wary of the risk of major civil litigation Far East cable and Shanghai in International Trade Co., Ltd. on December 25, 2007, the raw materials of copper forward purchase contract and its supplementary agreement disputes. As of press, the case is still pending. The drug industry said it was not yet able to make a reliable judgment on the outcome of the case and the specific effects of the verdict on both sides.